sutro biopharma - Robuta Search

https://www.biospace.com/press-releases/sutro-biopharma-reports-full-year-2024-financial-results-and-business-highlights Sutro Biopharma Reports Full Year 2024 Financial Results and Business Highlights - BioSpace 2024 financial results sutro biopharma full year https://www.bio.org/node/42481 David Pauling, IP Litigation Group Co-Chair, Sutro Biopharma, Inc. | BIO David Pauling currently holds the position of Chief Administrative Officer and General Counsel at Sutro Biopharma, Inc. He joined Sutro in 2011 and has since... ip litigation co chair sutro biopharma david pauling https://www.home.saxo/nl-be/markets/stocks/stro-xnas Sutro Biopharma Inc. aandeel | Saxo Bank Sutro Biopharma Inc is a clinical-stage drug discovery, development, and manufacturing company. sutro biopharma inc aandeel saxo bank https://www.biospace.com/sutro-biopharma-appoints-dr-hans-peter-gerber-as-chief-scientific-officer Sutro Biopharma Appoints Dr. Hans-Peter Gerber as Chief Scientific Officer - BioSpace Sep 20, 2023 - Sutro Biopharma, Inc., a clinical-stage oncology company pioneering site-specific and novel-format antibody drug conjugates, announced the appointment of... chief scientific officer sutro biopharma hans peter https://finviz.com/news/321632/sutro-biopharma-to-participate-in-upcoming-investor-conferences Sutro Biopharma to Participate in Upcoming Investor Conferences Stock screener for investors and traders, financial visualizations. sutro biopharma to participate upcoming investor conferences https://ir.sutrobio.com/ Sutro Biopharma, Inc. (STRO) At Sutro, we are advancing a cutting-edge, next-generation antibody-drug conjugate (ADC) platform designed to deliver single- and dual-payload ADCs that enable... sutro biopharma inc stro https://www.biospace.com/sutro-biopharma-appoints-dr-barbara-leyman-as-chief-business-development-officer Sutro Biopharma Appoints Dr. Barbara Leyman as Chief Business Development Officer - BioSpace business development officer sutro biopharma dr barbara https://stockhouse.com/companies/opinion?symbol=stro NDAQ:STRO | Opinion & Analysis | Sutro Biopharma Inc Get insightful analysis and opinion about Sutro Biopharma Inc (NDAQ:STRO) and the market in general. Stockhouse Editors and other Contributors weigh in. sutro biopharma ndaq stro opinion analysis https://www.biospace.com/sutro-biopharma-to-present-at-the-jmp-securities-life-sciences-conference Sutro Biopharma to Present at the JMP Securities Life Sciences Conference - BioSpace Jun 18, 2019 - Sutro Biopharma, Inc. announced that Steve Worsley, Chief Business Officer, will present a company overview at the JMP Securities Life Sciences Conference on... sutro biopharma https://www.home.saxo/en-sg/markets/stocks/stro-xnas Sutro Biopharma Inc. stock | Saxo Sutro Biopharma Inc is a clinical-stage drug discovery, development, and manufacturing company. sutro biopharma inc stock saxo https://www.prnewswire.com/news-releases/sutro-biopharma-to-receive-milestone-payment-for-novel-bispecific-antibody-drug-conjugate-targeting-solid-tumors-300931463.html Sutro Biopharma to Receive Milestone Payment for Novel Bispecific Antibody Drug Conjugate Targeting... /PRNewswire/ -- Sutro Biopharma, Inc. (NASDAQ: STRO) today announced that it has achieved a milestone under its collaboration and license agreement with the... https://www.biospace.com/press-releases/sutro-biopharma-to-highlight-its-next-generation-exatecan-and-dual-payload-adc-programs-in-presentations-at-aacr-2025 Sutro Biopharma to Highlight its Next-Generation Exatecan and Dual-Payload ADC Programs in... https://www.prnewswire.com/news-releases/sutro-biopharma-to-present-at-the-hc-wainwright-21st-annual-healthcare-conference-300910950.html Sutro Biopharma to Present at the H.C. Wainwright 21st Annual Healthcare Conference /PRNewswire/ -- Sutro Biopharma, Inc. (NASDAQ: STRO) today announced that Bill Newell, CEO of Sutro Biopharma, will present a corporate overview at the H.C.... https://www.pharmaceutical-technology.com/data-insights/luveltamab-tazevibulin-sutro-biopharma-net-present-value/ Risk Adjusted Net Present Value: What is the current valuation of Sutro Biopharma's Luveltamab... Dec 13, 2024 - Luveltamab Tazevibulin is a monoclonal antibody conjugated commercialized by Sutro Biopharma, with a leading Phase III program in Peritoneal Cancer.